EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The AXL inhibitor bemcentinib overcomes microenvironment‐mediated resistance to pioglitazone in acute myeloid leukemia

Jaja Zhu, Hippolyte Guérineau, Anne-Margaux Lefebvre-Fortané, Laetitia Largeaud, Juliette Lambert, Philippe Rousselot, Maèva Boudouin, Julien Calvo, Stéphane Prost, Sylvain Clauser, Valérie Bardet iD

The FEBS Journal · 2025

DOI: 10.1111/febs.17263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Jaja Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire Cellules Souches et Applications Thérapeutiques, UMR INSERM 1184, Commissariat à l'Energie Atomique et Aux Energies Alternatives, Fontena…. Hauptthemen laut MEDLINE: Axl Receptor Tyrosine Kinase, Pioglitazone, Leukemia, Myeloid, Acute, Receptor Protein-Tyrosine Kinases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Association Laurette Fugain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prognosis of acute myeloid leukemia (AML) remains poor especially in older patients who are ineligible for standard chemotherapy or have refractory disease. Here, we study the potential of Peroxisome Proliferator‐Activated Receptor (PPAR)‐γ agonist pioglitazone to improve the treatment of AML. We show that pioglitazone exerts an anti‐proliferative and anti‐clonogenic effect on AML cell lines KG‐1a, MOLM‐14 and OCI‐AML3 and on primary cultures from AML patients. However, co‐culture of AML cells with stromal cells mimicking the bone marrow microenvironment counteracts this effect, suggesting the existence of a stroma‐mediated resistance mechanism to pioglitazone. We show that pioglitazone treatment upregulates the receptor AXL in AML cells at the mRNA and protein level, allowing AXL to be phosphorylated by its ligand Gas6, which is secreted by the stroma. Addition of exogenous Gas6 or stromal cell conditioned medium also abolishes the anti‐proliferative effect of pioglitazone, with an increase in AXL phosphorylation observed in both conditions. Co‐incubation with the AXL inhibitor bemcentinib restored the anti‐leukemic activity of pioglitazone in the presence of stromal cells by reducing AXL phosphorylation to its baseline level. We also confirm that this resistance mechanism is PPAR‐γ‐dependent as stromal cells invalidated for PPAR‐γ are unable to inhibit the antileukemic effect of pioglitazone. Altogether, we suggest that pioglitazone treatment exerts an anti‐leukemic effect but concomitantly triggers a stroma‐mediated resistance mechanism involving the Gas6/AXL axis. We demonstrate that a combination of pioglitazone with an AXL inhibitor overcomes this mechanism in primary cultures and AML cell lines and exerts potent anti‐leukemic activity requiring further evaluation in vivo through murine xenograft pre‐clinical models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Axl Receptor Tyrosine KinasePioglitazoneLeukemia, Myeloid, AcuteReceptor Protein-Tyrosine KinasesDrug Resistance, NeoplasmProto-Oncogene ProteinsTumor MicroenvironmentBenzocycloheptenesPPAR gammaHumansCell ProliferationIntercellular Signaling Peptides and ProteinsPhosphorylationCell Line, TumorCoculture TechniquesStromal CellsProtein Kinase InhibitorsTriazolesGrowth Arrest-Specific Protein 6

Stichwörter der Autor:innen

AxlGas6PPAR‐gammaacute myeloid leukemiabemcentinibpioglitazone

Substanzen

Axl Receptor Tyrosine KinasePioglitazoneReceptor Protein-Tyrosine KinasesProto-Oncogene ProteinsBenzocycloheptenesPPAR gammaIntercellular Signaling Peptides and ProteinsProtein Kinase InhibitorsTriazolesGrowth Arrest-Specific Protein 6

Autor:innen und Institutionen

  • Laboratoire Cellules Souches et Applications Thérapeutiques, UMR INSERM 1184, Commissariat à l'Energie Atomique et Aux Energies Alternatives, Fontenay-Aux-Roses, France.
  • Service d'Hématologie-Immunologie-Transfusion, AP-HP. Université Paris-Saclay, CHU Ambroise Paré, Université Versailles-Saint Quentin-Université Paris-Saclay, Montigny le Bretonneux, France.
  • Service d'Hématologie et d'Oncologie, Centre Hospitalier André Mignot, Université Versailles Saint Quentin-Université Paris Saclay, Montigny le Bretonneux, France.

ORCID-Profile: Valérie Bardet

Förderung

  • Association Laurette Fugain

Zitieren

APA

Zhu, J., Guérineau, H., Lefebvre-Fortané, A. M., Largeaud, L., Lambert, J., Rousselot, P., Boudouin, M., Calvo, J., Prost, S., Clauser, S., & Bardet, V. (2025). The AXL inhibitor bemcentinib overcomes microenvironment‐mediated resistance to pioglitazone in acute myeloid leukemia. The FEBS Journal. https://doi.org/10.1111/febs.17263

Vancouver

Zhu J, Guérineau H, Lefebvre-Fortané AM, Largeaud L, Lambert J, Rousselot P, et al. The AXL inhibitor bemcentinib overcomes microenvironment‐mediated resistance to pioglitazone in acute myeloid leukemia. The FEBS Journal. 2025. doi:10.1111/febs.17263

BibTeX
@article{Zhu2025,
  author = {Zhu, Jaja and Guérineau, Hippolyte and Lefebvre-Fortané, Anne-Margaux and Largeaud, Laetitia and Lambert, Juliette and Rousselot, Philippe and Boudouin, Maèva and Calvo, Julien and Prost, Stéphane and Clauser, Sylvain and Bardet, Valérie},
  title = {The AXL inhibitor bemcentinib overcomes microenvironment‐mediated resistance to pioglitazone in acute myeloid leukemia},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.17263}
}
Kostenlos starten →